Obesity and the revolution of multi-indication therapies

Download this free whitepaper to discover how ICON is reshaping clinical development strategies through multi-indication drug development in obesity and its comorbidities. As GLP-1 receptor agonists redefine therapeutic possibilities, a multi-indication approach has emerged as a key pathway for maximising impact. ICON explores how sponsors can streamline development with synergistic strategies, adaptive trials, and precision phenotyping. This whitepaper draws from an industry-wide survey to examine how innovative trial designs and real-world evidence are enabling rapid label expansion, operational efficiencies and broader market access in obesity-related therapies.